Finnish neurotechnology company Audicin has successfully secured $1.9 million in a recent funding round, elevating its total capital to approximately $3 million. The company specializes in real-time nervous system regulation through adaptive audio technology designed to enhance focus, sleep, and stress recovery. This new capital injection is earmarked to accelerate the commercialization of its core products and fuel expansion into new markets.
Innovating Nervous System Regulation
Audicin's approach is rooted in a combination of brainwave entrainment, auditory engineering, and music neuroscience. Its platform delivers background listening sessions that dynamically adapt to the user's physiological state throughout the day. The core mission is to provide continuous nervous system support to improve productivity and overall well-being.
A key feature of the technology is its passive operation, which seamlessly integrates with popular wearable devices like Oura, Apple Watch, and Garmin. By analyzing biometric data, the system provides real-time audio adjustments without requiring active user engagement or dedicated time. This allows for nervous system regulation to occur unobtrusively in the background of daily life.
Strategic Product Expansion
The company is advancing its reach through "Audicin for Apps," a software development kit (SDK) for third-party platforms. This tool enables digital health and consumer applications to embed Audicin's regulation protocols directly into their user experiences. Sessions can be triggered automatically by in-app events, time of day, or biometric signals from connected devices.
To address environments with device restrictions, Audicin is also developing a standalone, offline Sleep Headband. This product is designed for use in sectors such as healthcare and defense where mobile phones are not permitted. The headband delivers pre-configured recovery programs based on low-frequency brainwave protocols associated with deep, restorative sleep.
Driving Commercial Growth and Market Adoption
Audicin’s latest funding round attracted backing from private investors, Oura co-founder Petteri Lahtela, and Business Finland’s Deep Tech Accelerator, signaling strong confidence in its technology and commercial potential. Building on its earlier pre-seed round, the company has developed an $8 million sales pipeline across defense, athletic performance, and wellness, while growing users by 40% in 12 weeks without paid marketing and doubling iOS revenue.
CEO Laura Avonius said Audicin aims to make nervous system support part of everyday life by helping users manage stress and cognitive load in real time, even in high-security environments. Lahtela added that the company’s technology stands out because it works seamlessly during daily activities, positioning it strongly for both enterprise and consumer markets.
With its new funding, Audicin is poised to significantly scale its innovative nervous system regulation technology. The company's strategy to embed its solutions into existing platforms and create hardware for specialized environments positions it for broad adoption. This move signals a shift towards more integrated, passive wellness tools that support human performance and resilience around the clock.